Suchergebnisse - "Capdevila, Jaume"

PubPharm (12)

1

Methodology of the SORENTO clinical trial : a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

enthalten in: Trials | 2024

von Singh, S. | Ferone, D. | Capdevila, J. | +8

2

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

enthalten in: The New England journal of medicine | 2023

von Hadoux, J. | Elisei, R. | Brose, M. | +122

3

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311) : a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Brose, M. | Robinson, B. | Sherman, S. | +12

4

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Bahadoer, R. | Dijkstra, E. | van Etten, B. | +118

CommentIn: Lancet Oncol. 2021 Jan;22(1):2-3. - PMID 33301739

5

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial

enthalten in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2020

von van der Valk, M. | Marijnen, C. | van Etten, B. | +18

ErratumIn: Radiother Oncol. 2020 Jun;147:e1. - PMID 32564889

6

Genomic profiling of NETs : a comprehensive analysis of the RADIANT trials

enthalten in: Endocrine-related cancer | 2019

von Yao, J. | Garg, A. | Chen, D. | +13

7

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

enthalten in: The Journal of clinical endocrinology and metabolism | 2016

von Robinson, B. | Schlumberger, M. | Wirth, L. | +8

8

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors : Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2016

von Yao, J. | Pavel, M. | Lombard-Bohas, C. | +11

CommentIn: J Clin Oncol. 2017 May 1;35(13):1487-1488. - PMID 28113025

9

Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer

enthalten in: British journal of clinical pharmacology | 2016

von Gupta, A. | Jarzab, B. | Capdevila, J. | +2

10

Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors : a subgroup analysis of the phase III RADIANT-3 trial

enthalten in: Pancreas | 2015

von Lombard-Bohas, C. | Yao, J. | Hobday, T. | +7